Back

Impact of Androgenic Anabolic Steroids on Cardiovascular Health in Men and Women - PART OF THE FITNESS DOPING IN DENMARK (FIDO-DK) STUDY

Buhl, L. F.; Christensen, L. L.; Hjortebjerg, R.; Diederichsen, A. C. P.; Hasific, S.; Andersen, M. S.; Harders, S.; Lillevang-Johansen, M.; Glintborg, D.; Thevis, M.; Kistorp, C.; Rasmussen, J. J.; Lindholt, J. S.; Hjerrild, C.; Frystyk, J.

2024-11-19 cardiovascular medicine
10.1101/2024.11.18.24317516
Show abstract

BackgroundIllicit use of anabolic androgenic steroids (AAS) is common among recreational athletes, yet comprehensive studies on adverse cardiovascular outcomes, especially in female AAS users, are lacking. MethodsA cross-sectional study of recreational athletes of women and men was conducted, involving active and previous AAS users and non-users aged [&ge;]18 years. Previous use was defined as discontinuation of AAS at least three months prior to study. Primary outcomes included atherosclerosis (carotid, femoral, and coronary artery plaques) and cardiac function, assessed using vascular ultrasound, coronary computed tomography angiography and echocardiography. ResultsMedian age was 36 years for active users (n=80, 19 women), 35 years for previous users (n=26, 8 women), and 40 years for non-users (n=58, 16 women) (p=NS). Median AAS usage period was 2.2 years for both active and previous users; the latter group had discontinued intake 2.5 years before study (range: 3 months to 29 years). There was no group differences when comparing the number of femoral/carotid artery plaques, the coronary artery calcium (CAC) score or the number of non-calcified plaques. However, confounder-adjusted logistic regression showed associations between cumulative AAS use and a positive CAC score (OR: 1.23, 95% CI: 1.09-1.39, p=0.001) and the presence of non-calcified plaque (OR: 1.17, 95% CI: 1.05-1.30, p=0.004), respectively, when comparing previous and ongoing users vs. non-users. These associations were also present in men, but not women. Moreover, >5 years of AAS use increased the fraction of athletes with increased severity of calcifications (p=0.043). Echocardiography showed that active AAS using males and females had impaired left ventricular global longitudinal strain (LVGLS) and right ventricular global longitudinal strain (RVGLS) compared to sex-matched non-users (p<0.001). Multivariable analysis showed that cumulative AAS use correlated with worsening of LVGLS (p=0.002) and RVGLS (p=0.001). Finally, after 5 years of cumulative AAS use, nearly all athletes had ventricular mass above and left ventricular ejection fraction below the median of normal range. ConclusionIn men, the cumulative lifetime AAS exposure was an independent predictor of coronary atherosclerosis. However, both male and female AAS users share risks of myocardial dysfunction, underscoring significant cardiovascular risks across genders. CLINICAL PERSPECTIVEKey observations from the study: O_LIIn recreational athletes, the accumulated lifetime AAS exposure associates with a higher prevalence of non-calcified plaques and coronary artery calcification in male recreational athletes. C_LIO_LIOur study suggests that more than 5 years of AAS use constitutes a threshold beyond which the development of coronary calcifications significantly increases compared to non-users. C_LIO_LIIn addition to compromised left ventricular systolic and diastolic function, AAS users exhibited significantly reduced right ventricular function, indicating a biventricular cardiac impact of AAS. C_LIO_LIMale and female AAS users showed similar patterns of cardiac deterioration. C_LI These findings highlight the significant cardiovascular risks associated with AAS use in both male and female recreational athletes, underscoring the importance of targeted research, educational programs, information campaigns, and intervention strategies for this population, regardless of gender.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Journal of the American Heart Association
based on 92 papers
Top 0.8%
15.9%
2
PLOS ONE
based on 1737 papers
Top 39%
12.9%
3
Frontiers in Cardiovascular Medicine
based on 33 papers
Top 1%
7.8%
4
European Journal of Preventive Cardiology
based on 12 papers
Top 0.1%
6.6%
5
Atherosclerosis
based on 16 papers
Top 0.7%
4.6%
6
BMJ Open
based on 553 papers
Top 24%
4.6%
50% of probability mass above
7
Frontiers in Neurology
based on 74 papers
Top 5%
2.9%
8
Circulation
based on 37 papers
Top 3%
2.9%
9
Open Heart
based on 18 papers
Top 2%
2.9%
10
Journal of Clinical Medicine
based on 77 papers
Top 5%
2.9%
11
European Heart Journal
based on 14 papers
Top 2%
2.9%
12
The American Journal of Cardiology
based on 15 papers
Top 2%
2.5%
13
Scientific Reports
based on 701 papers
Top 64%
2.3%
14
Cureus
based on 64 papers
Top 10%
1.6%
15
Arteriosclerosis, Thrombosis, and Vascular Biology
based on 11 papers
Top 1%
1.4%
16
BMC Cardiovascular Disorders
based on 11 papers
Top 2%
1.4%
17
International Journal of Environmental Research and Public Health
based on 116 papers
Top 16%
1.4%
18
Heart
based on 10 papers
Top 2%
1.4%
19
Nutrients
based on 43 papers
Top 3%
1.4%
20
Hypertension
based on 20 papers
Top 3%
1.2%
21
eLife
based on 262 papers
Top 24%
1.2%
22
International Journal of Cardiology
based on 13 papers
Top 3%
0.8%
23
JMIR Research Protocols
based on 18 papers
Top 3%
0.8%
24
Circulation: Genomic and Precision Medicine
based on 30 papers
Top 5%
0.7%
25
PLOS Medicine
based on 95 papers
Top 17%
0.7%
26
Journal of Thrombosis and Haemostasis
based on 10 papers
Top 2%
0.7%
27
Journal of the American College of Cardiology
based on 11 papers
Top 3%
0.7%
28
Frontiers in Physiology
based on 18 papers
Top 3%
0.7%